Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer.
Mediocre balance sheet with concerning outlook.
Share Price & News
How has Agenus's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
AGEN outperformed the Biotechs industry which returned -8.1% over the past year.
AGEN outperformed the Market in United States of America which returned -0.4% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is Agenus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAgenus (NASDAQ:AGEN) Debt But No Earnings
1 month ago | Simply Wall StThe Agenus (NASDAQ:AGEN) Share Price Is Down 44% So Some Shareholders Are Getting Worried
2 months ago | Simply Wall StBefore You Buy Agenus Inc. (NASDAQ:AGEN), Consider Its Volatility
Is Agenus undervalued based on future cash flows and its price relative to the stock market?
In this section, we usually try to help investors determine whether Agenus is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Agenus has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of AGEN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore potentially undervalued companies in the pharmaceuticals & biotech industry.
How is Agenus expected to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Agenus's revenue is expected to grow by 17.9% yearly, however this is not considered high growth (20% yearly).
Agenus is not considered high growth as it is expected to be loss making for the next 1-3 years.
Agenus's revenue growth is expected to exceed the United States of America market average.
Unable to compare Agenus's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Agenus's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Agenus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
How has Agenus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Agenus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Agenus's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Agenus's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Agenus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
Return on Assets
It is difficult to establish if Agenus has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Agenus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
How is Agenus's financial position?
Financial Position Analysis
Agenus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Agenus's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Agenus has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
Irrelevant to check if Agenus's debt level has increased considering it has negative shareholder equity.
Low level of unsold assets.
Agenus has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Agenus has sufficient cash runway for more than 3 years based on current free cash flow.
Agenus has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -8.1% each year.
What is Agenus's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Agenus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Agenus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Agenus has not reported any payouts.
Unable to verify if Agenus's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Agenus has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
What is the CEO of Agenus's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Garo Armen (66yo)
Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agen ...
CEO Compensation Analysis
Garo's remuneration is higher than average for companies of similar size in United States of America.
Garo's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
The average tenure for the Agenus management team is less than 2 years, this suggests a new team.
Board Age and Tenure
The average tenure for the Agenus board of directors is over 10 years, this suggests they are a seasoned and experienced board.
No 3 month open market individual insider trading information.
Global Head of Clinical Operations
- Tenure: 0.4yrs
Chris Cortis (51yo)
Chief Strategy Officer & Head of Finance
- Tenure: 1.2yrs
VP & Head of Commercial
- Tenure: 0.1yrs
Chief Operating Officer
- Tenure: 0.8yrs
- Compensation: $986.47k
Christine Klaskin (53yo)
VP of Finance
- Compensation: $497.48k
VP, General Counsel & Secretary
- Tenure: 1.1yrs
Alex Duncan (57yo)
CTO & Head of Research
- Tenure: 3.6yrs
- Compensation: $833.26k
Ozer Baysal (63yo)
Chief Commercial Officer & Head of HR
- Tenure: 2.1yrs
- Compensation: $461.73k
Head of Translational Medicine & Bioinformatics
- Tenure: 1.6yrs
Garo Armen (66yo)
- Tenure: 25.6yrs
- Compensation: $2.57m
Garo Armen (66yo)
- Compensation: $2.57m
Ulf Wiinberg (61yo)
- Tenure: 3.3yrs
- Compensation: $195.08k
Wadih Jordan (84yo)
- Tenure: 16.4yrs
- Compensation: $113.70k
Tim Wright (61yo)
- Tenure: 10.6yrs
- Compensation: $218.70k
Brian Corvese (61yo)
- Tenure: 12.4yrs
- Compensation: $257.58k
Allison Jeynes-Ellis (53yo)
- Tenure: 0.8yrs
- Compensation: $167.78k
Agenus Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Agenus Inc.
- Ticker: AGEN
- Exchange: NasdaqCM
- Founded: 1994
- Industry: biotechnology
- Sector: pharmaceuticals & biotech
- Market Cap: US$388.595m
- Shares outstanding: 137.31m
- Website: Click here
Number of Employees
- Agenus Inc.
- 3 Forbes Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AGEN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2000|
|AJ81||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2000|
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an a ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/08/17 23:32|
|End of Day Share Price||2019/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.